Peptide analogs in the therapy of prostate cancer

Prostate

Volumn 45, Issue 2, 2000, Pages 158-166

  Schally, Andrew V ^a,b   Comaru Schally, Ana Maria ^a,b   Plonowski, Artur ^a,b   Nagy, Attila ^a,b   Halmos, Gabor ^a,b   Rekasi, Zoltan ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agonists of LH RH; Antagonists of LH RH; Bombesin antagonists; GH RH antagonists; Targeted cytotoxic analogs of LH RH, bombesin, and somatostatin or cytotoxic peptide analogs

Indexed keywords

2 PYRROLINODOXORUBICIN; ABARELIX; ANDROGEN; ANTIANDROGEN; BOMBESIN; CETRORELIX; DOXORUBICIN; GASTRIN RELEASING PEPTIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; PEPTIDE DERIVATIVE; SOMATOSTATIN DERIVATIVE;

BOLUS INJECTION; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CYTOTOXICITY; HORMONE DEPENDENCE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; TUMOR BIOPSY;

ANDROGENS; ANIMAL; BOMBESIN; CYTOTOXINS; GASTRIN-RELEASING PEPTIDE; GONADORELIN; HUMAN; MALE; PEPTIDES; PROSTATIC NEOPLASMS; SOMATOSTATIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0033809968     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K     Document Type: Review

References (58)

1. Future prospects in prostate cancer
2. Cancer statistics, 2000
3. Management of hormone refractory prostate cancer: Current standards and future prospects
4. Hypothalamic and other peptide hormones
5. Studies of prostatic cancer. I. Effect of castration, estrogens and androgen injections on serum phosphatases in metastatic carcinoma of the prostate
6. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp-6-LH-RH
7. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists
8. Evaluation and management of the man who has failed primary curative therapy for prostate cancer
9. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
10. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix
11. Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats
12. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice
13. Luteinizing hormone-releasing hormone [LH-RH] antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors
14. Responses to the antagonistic analog of LH-RH [SB-75] (Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
15. LH-RH antagonist SB-75 [Cetrorelix] as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invation of spinal cord
16. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer
17. Hormone-refractory [D3] prostate cancer: Refining the concept
18. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
19. Bombesin-like peptides: Of ligands and receptors
20. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer
21. 4] bombesin by tumor cells
22. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells
23. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation
24. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers
25. Bombesin stimulates growth of human prostatic cancer cells in vitro
26. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells
27. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer
28. 2 or its derivatives
29. Pseudononapeptide bombesin antagonists containing C-terminal Trp or D-Tpi
30. Somatostatin analog RC-160 and bombesin/gastrin releasing antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice
31. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate cancer xenografts in nude mice
32. LH-RH antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
33. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone intagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
34. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways
35. Chemotherapy targeted to hormone receptors on tumors. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
36. High expression of somatostatin receptors and mRNA for its receptor subtypes in organ-confined and locally advanced human prostate cancers
37. Antagonistic analogs of growth hormone-releasing hormone [GH-RH]: New potential antitumor agents
38. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
39. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II tumors
40. Growth hormone-releasing hormone an autocrine growth factor for small cell lung carcinoma
41. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
42. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers
43. Docetaxel [Taxotere]-based chemotherapy for hormone-refractory and locally advanced prostate cancer
44. High incidence of receptors for luteinizing hormone-releasing hormone [LHRH] and LHRH receptor gene expression in human prostate cancers
45. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
46. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
47. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
48. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin
49. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
50. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue AN-215
51. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer
52. Somatostatin receptors in human prostate and prostate cancer
53. 1]-octreotide scintigraphy
54. Somatostatin receptor scintigraphy
55. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
56. Targeted cytotoxic analogue of somatostatin AN-238 inhibits the growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses
57. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analog AN-238
58. Enzymatic activation of doxorubicin-peptide prodrug by prostate-specific antigen [advances in brief]